ID | 116065 |
Title Alternative | プロテアーゼ活性化型受容体2を介した活性化凝固第X因子シグナル経路は心房細動予防のための新しい治療標的である
Role of Protease-Activated Receptor 2 in AF
|
Author |
Matsuura, Tomomi
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Soeki, Takeshi
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Uematsu, Etsuko
Tokushima University
Hara, Tomoya
Shikoku Medical Center for Children and Adults
Kusunose, Kenya
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Ise, Takayuki
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Yamaguchi, Koji
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Yagi, Shusuke
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Yamada, Hirotsugu
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Wakatsuki, Tetsuzo
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Sata, Masataka
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
|
Keywords | atrial fibrillation
FXa
PAR2
inflammation
anticoagulants
|
Content Type |
Thesis or Dissertation
|
Description | Background: Activated factor X (FXa), which contributes to chronic inflammation via protease-activated receptor 2 (PAR2), might play an important role in atrial fibrillation (AF) arrhythmogenesis. This study aimed to assess whether PAR2 signaling contributes to AF arrhythmogenesis and whether rivaroxaban ameliorates atrial inflammation and prevents AF.
Methods and Results: In Study 1, PAR2 deficient (PAR2−/−) and wild-type mice were infused with angiotensin II (Ang II) or a vehicle via an osmotic minipump for 2 weeks. In Study 2, spontaneously hypertensive rats (SHRs) were treated with rivaroxaban, warfarin, or vehicle for 2 weeks after 8h of right atrial rapid pacing. The AF inducibility and atrial remodeling in both studies were examined. Ang II-treated PAR2−/− mice had a lower incidence of AF and less mRNA expression of collagen1 and collagen3 in the atrium compared to wild-type mice treated with Ang II. Rivaroxaban significantly reduced AF inducibility compared with warfarin or vehicle. In SHRs treated with a vehicle, rapid atrial pacing promoted gene expression of inflammatory and fibrosis-related biomarkers in the atrium. Rivaroxaban, but not warfarin, significantly reduced expression levels of these genes. Conclusions: The FXa–PAR2 signaling pathway might contribute to AF arrhythmogenesis associated with atrial inflammation. A direct FXa inhibitor, rivaroxaban, could prevent atrial inflammation and reduce AF inducibility, probably by inhibiting the pro-inflammatory activation. |
Journal Title |
Circulation Journal
|
ISSN | 13469843
13474820
|
NCID | AA11591968
|
Publisher | The Japanese Circulation Society
|
Volume | 85
|
Issue | 8
|
Start Page | 1383
|
End Page | 1391
|
Published Date | 2021-07-21
|
Remark | 内容要旨・審査要旨・論文本文の公開
本論文は,著者Tomomi Matsuuraの学位論文として提出され,学位審査・授与の対象となっている。 |
Rights | This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license. https://creativecommons.org/licenses/by-nc-nd/4.0/
|
EDB ID | |
DOI (Published Version) | |
URL ( Publisher's Version ) | |
FullText File | |
language |
eng
|
TextVersion |
ETD
|
MEXT report number | 甲第3527号
|
Diploma Number | 甲医第1497号
|
Granted Date | 2021-04-22
|
Degree Name |
Doctor of Medical Science
|
Grantor |
Tokushima University
|
departments |
University Hospital
Medical Sciences
|